tetano
Editor, Senior Moderator
Orbit
. 2022 May 2;1-5.
doi: 10.1080/01676830.2022.2062777. Online ahead of print.
Acute onset ocular myasthenia gravis after vaccination with the Oxford-AstraZeneca COVID-19 vaccine
Dominic I Maher[SUP] 1 [/SUP], Daniel Hogarty[SUP] 1 [/SUP], Elad Ben Artsi[SUP] 1 [/SUP]
Affiliations
Abstract
Myasthenia gravis (MG) is an autoimmune disease that results in muscle weakness and fatigability. Extraocular involvement may be the first sign of disease. It may be triggered by infections, stress, or medications. We describe a first reported case of ocular MG induced by the viral vector Oxford-AstraZeneca coronavirus disease (COVID-19) vaccine, detail the pathophysiology of vaccine-induced MG, and explore the impact of COVID-19 on MG patients.
Keywords: COVID-19; Oxford-AstraZeneca; ocular myasthenia gravis; vaccination.
. 2022 May 2;1-5.
doi: 10.1080/01676830.2022.2062777. Online ahead of print.
Acute onset ocular myasthenia gravis after vaccination with the Oxford-AstraZeneca COVID-19 vaccine
Dominic I Maher[SUP] 1 [/SUP], Daniel Hogarty[SUP] 1 [/SUP], Elad Ben Artsi[SUP] 1 [/SUP]
Affiliations
- PMID: 35499172
- DOI: 10.1080/01676830.2022.2062777
Abstract
Myasthenia gravis (MG) is an autoimmune disease that results in muscle weakness and fatigability. Extraocular involvement may be the first sign of disease. It may be triggered by infections, stress, or medications. We describe a first reported case of ocular MG induced by the viral vector Oxford-AstraZeneca coronavirus disease (COVID-19) vaccine, detail the pathophysiology of vaccine-induced MG, and explore the impact of COVID-19 on MG patients.
Keywords: COVID-19; Oxford-AstraZeneca; ocular myasthenia gravis; vaccination.